TY - JOUR
T1 - Emerging treatment options for acute lymphoblastic leukemia
T2 - Focus on CAR T-cell therapy
AU - Brown, Patrick A.
AU - Shah, Bijal
N1 - Funding Information:
Dr. Brown has disclosed that he has received consulting fees/honoraria from Amgen Inc., Novartis Pharmaceuticals Corporation, and Shire. Dr. Shah has disclosed that he has received consulting fees/honoraria from Adaptive Biotechnologies and grant/research support from Incyte Corporation.
Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of diseases with different morphologic, cytogenetic, and molecular subgroups, some of which have significant therapeutic implications. It typically presents with an aggressive clinical course, and among adults, responds poorly to standard chemotherapy, and carries a high risk for relapse. Despite the significant progress made in inducing remission, frequent relapses remain a challenge. Novel drugs, such as potent later-generation tyrosine kinase inhibitors, antibody-drug conjugates, bispecific monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies, are being investigated in patients with ALL. This summary describes therapies currently approved for the treatment of patients with ALL, identifies emerging targeted immunotherapies for patients with ALL, and discusses adverse events and mechanisms of resistance.
AB - Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of diseases with different morphologic, cytogenetic, and molecular subgroups, some of which have significant therapeutic implications. It typically presents with an aggressive clinical course, and among adults, responds poorly to standard chemotherapy, and carries a high risk for relapse. Despite the significant progress made in inducing remission, frequent relapses remain a challenge. Novel drugs, such as potent later-generation tyrosine kinase inhibitors, antibody-drug conjugates, bispecific monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies, are being investigated in patients with ALL. This summary describes therapies currently approved for the treatment of patients with ALL, identifies emerging targeted immunotherapies for patients with ALL, and discusses adverse events and mechanisms of resistance.
UR - http://www.scopus.com/inward/record.url?scp=85048285203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048285203&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0048
DO - 10.6004/jnccn.2018.0048
M3 - Article
C2 - 29784748
AN - SCOPUS:85048285203
SN - 1540-1405
VL - 16
SP - 651
EP - 655
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5S
ER -